We read the article by Largillier et al. [1] about the prognostic markers in women with metastatic breast cancer with great interest. During follow-up, metastasis was reported to have developed in only 21% of all breast cancer patients. The patients' characteristics showed that most of the patients had undergone tumorectomy (53%). Of patients who developed metastasis, 37% were node negative and 48.3% were T1 status. These findings point out that most of the patients were in early stage at the time of diagnosis. In this study, only 60% of the 4958 consecutive patients received adjuvant therapy, including chemotherapy, hormonotherapy, and combination of chemotherapy and hormonotherapy. Although 84% of patients who developed metastasis were hormone receptor positive, only 31% received hormonotherapy. The authors reported that 32% of patients received adjuvant chemotherapy and this rate was 49% in patients who developed metastasis. These findings show that, in this study, the patients were insufficiently treated. Most of the recently published studies have revealed that both adjuvant letters to the editor Annals of Oncology 192 | letters to the editor
chemotherapy and hormonotherapy improved both survival and recurrence-free survival in early-stage breast cancer [2, 3] . According to the National Comprehensive Cancer Network guidelines, patients with node positive or with tumors >1 cm in diameter are appropriate for systemic adjuvant therapy (chemotherapy and/or endocrine therapy if hormone receptor status is positive) [4] . The guideline recommends also chemotherapy for node-negative patients if hormone receptor is negative and additively recommends chemotherapy and hormonotherapy together if hormone receptor is positive. Adjuvant therapy is useful for most of patients with breast cancer and prolongs survival period. But in the study presented, the median survival for patients who did not take adjuvant chemotherapy was better than those who received adjuvant chemotherapy (31 versus 18 months). Furthermore, the results of multivariate analysis revealed out an association of poor survival in patients with metastatic breast cancer. Probably, the prolonged survival after the year 2000 in the study is due to new therapeutics such as taxanes and trastuzumab being used for patients with breast cancer. We think that adjuvant therapy is a poor prognostic factor because the patients in this study were insufficiently treated. We also think that the unfavorable results of the study on adjuvant chemotherapy may give a wrong message to clinicians and breast cancer patients. 
